Levitra Talks
SUBSCRIPTION
  LInks  
Bookmark this Site
 
 Year 2009
   » March 2009
 Year 2007
 Year 2006
 Year 2005
 Year 2004
 Year 2003
 Levitra information
   
Get To Know ED
What is Levitra?
  » FDA Approval
» History & Present Status
Who is Behind Levitra?
Levitra Expectations
Tips for First Timers
Patient Leaflet
Levitra Side Effects
  » Levitra Safety
Levitra Pharmacology
  » Levitra Clinical Data
PDE5 Inhibitors
ED Quiz
Levitra News
   
 
 

  News Home » March 2009


Levitra- Very Effective for ED Patients with Underlying Illness

Monday, 30 March 2009

Levitra has been found to improve erectile function, the effectiveness of penetration and the number of successful sexual intercourse episodes in men suffering from impotence as a side effect of diabetes, hypertension, metabolic syndrome and dyslipidaemia according to research announced at the 24th Annual European Association of Urology Congress.

According to the lead researcher, Professor Ian Eardley from the Department of Urology at St. James's University Hospital in Leeds explained that the research was based on patient information from thirteen different placebo controlled, double blind, randomised and flexible dose clinical trials done over the last few years.

The researchers which was originally carried out to see whether using medications for cardiovascular problems along with the Levitra drug had any impact on whether the Levitra worked as well and were happy to report that they not lessen the effectiveness or the safety of the Levitra drug.

The clinical trials were done using different doses of Levitra from 5mg to 20mg and all of them were well tolerated irrespective of whether the men were suffering from any underlying medical conditions or using any other medications. The evaluation of the extent of erectile function was done using the International Index of Erectile Function questionnaires.


Disclaimer
| Levitra | Levitra Articles
Levitra ® is a registered trademark of Bayer AG and GlaxoSmithKline PLC.
Copyright © 2009 levitratalks.com, All rights reserved.